<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) is a preleukaemic condition with myeloproliferative features, and classified as a part of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Other than <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> and <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi>, there is less evidence that chemotherapeutic drugs are associated with therapy-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We present a patient who developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> within 2 years of <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-based chemotherapy for a metastatic <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>He received a cumulative dose of 240 mg/m(2) of <z:chebi fb="2" ids="27899">cisplatin</z:chebi>, and 1123 mg/m(2) of <z:chebi fb="2" ids="31355">carboplatin</z:chebi> before developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The cytogenetic study revealed <z:mp ids='MP_0004027'>trisomy</z:mp> 8 </plain></SENT>
<SENT sid="5" pm="."><plain>This is the first reported case that links <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-based therapy with development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> with <z:mp ids='MP_0004027'>trisomy</z:mp> 8 </plain></SENT>
<SENT sid="6" pm="."><plain>Although the relationship between <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> therapy and the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> is difficult to assess due to combinational nature of therapy in most cases, physicians should consider the possibility of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> in patients with symptoms or signs suggestive of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematologic malignancy</z:e> after <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> therapy </plain></SENT>
</text></document>